An Evaluation of the Efficacy and Safety Profile of Inula Racemosa in Patients of Restrictive Lung Diseases
DOI:
https://doi.org/10.37591/rrjomst.v4i3.1148Abstract
In this paper, we explain the procedure to evaluate the efficacy and safety profile of Inula racemosa in patients of restrictive lung diseases. The patients included in this study were selected from the outpatient clinic of a tertiary care hospital in North India. The present study was initiated on 45 patients suffering from restrictive lung diseases, 31 of these patients were followed up for 6 weeks. Remaining patients did not cooperate for the follow up study. The criteria for including the patients in the study were aged between 10 years and 60 years, history of cough and breathlessness for at least two years and patients not taking any steroid at least 15 days prior to the starting of the study. The patients having coexisting respiratory infection, smokers, patients with associated diseases like diabetes, hypertension or renal diseases and pregnant women were excluded from the study. The breathlessness was the most commonest complain with a high mean score (2.3 ± 0.03) than others and least being crepts with lowest mean score (0.30) at Day 0. A significant (p< 0.05) change in cough, expectoration and breathlessness was observed from Day 0 to Day 15. The expectoration and crepts became nil at Day 45 and significant (p<0.05) change was note in cough, breathlessness and rhonchi. The significant (p<0.01) increase was found in FVC and FEV from Day 0 to Day 45. However, there was an increase the FEV/FVC ratio from Day 0 to Day 45, however, this was statistically insignificant (p>0.01). The percentage change was higher in FEV (16.5%) than FVC (15%) and FEV/FVC (2.8%). Since, Inula racemosa has significant effect on clinical signs and symptoms as well as on pulmonary function tests among lung patients, this can be used for long term treatment.
Keywords: Inula racemosa, Lung diseases, Efficacy and safety
Cite this Article
Srivastava S, Pathak M, Dhungana HN. An evaluation of the efficacy and safety profile of inula racemosa in patients of restrictive lung diseases. Research & Reviews: Journal of Medical Science and Technology. 2015; 4(3): 18–21p
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
